TY - JOUR
T1 - Prospective nanoparticle treatments for lymphangioleiomyomatosis
AU - Landh, Emelie
AU - Wang, Roger
AU - Moir, Lyn M.
AU - Traini, Daniela
AU - Young, Paul M.
AU - Ong, Hui Xin
PY - 2022/1/21
Y1 - 2022/1/21
N2 - Introduction: Lymphangioleiomyomatosis (LAM) is a rare lung disease that is characterized by smooth muscle-like cell growth in the lungs. The current available oral treatment rapamycin slows down the disease progression but does not result in a cure. Rapamycin is also limited by its low bioavailability and dose-related adverse side effects. New treatments are, therefore, underway to investigate alternative targets and combination therapies for LAM. In recent years, much focus has been on the development of therapies based on inhaled nanotechnology using carriers to deliver drugs, as it is shown to improve drug solubility, local targeted treatment, and bioavailability. Areas covered: This review, therefore, focuses on future prospective treatments for LAM using nanoparticles and lipid-based nanocarriers, including liposomes, solid lipid nanoparticles, micelles, and polymeric nanoparticles. It also investigates how nanoparticles’ physicochemical factors such as size and charge can affect the treatment of both pulmonary and extrapulmonary LAM. Expert opinion: Advanced clinical research is still needed to demonstrate the full potential and drive future commercialization of LAM treatments delivered via inhaled lipid nanobased formulations. If successful, the resultant effects will be seen in the improvement in the life expectancy and life quality of LAM patients.
AB - Introduction: Lymphangioleiomyomatosis (LAM) is a rare lung disease that is characterized by smooth muscle-like cell growth in the lungs. The current available oral treatment rapamycin slows down the disease progression but does not result in a cure. Rapamycin is also limited by its low bioavailability and dose-related adverse side effects. New treatments are, therefore, underway to investigate alternative targets and combination therapies for LAM. In recent years, much focus has been on the development of therapies based on inhaled nanotechnology using carriers to deliver drugs, as it is shown to improve drug solubility, local targeted treatment, and bioavailability. Areas covered: This review, therefore, focuses on future prospective treatments for LAM using nanoparticles and lipid-based nanocarriers, including liposomes, solid lipid nanoparticles, micelles, and polymeric nanoparticles. It also investigates how nanoparticles’ physicochemical factors such as size and charge can affect the treatment of both pulmonary and extrapulmonary LAM. Expert opinion: Advanced clinical research is still needed to demonstrate the full potential and drive future commercialization of LAM treatments delivered via inhaled lipid nanobased formulations. If successful, the resultant effects will be seen in the improvement in the life expectancy and life quality of LAM patients.
KW - inhalation
KW - Lymphangioleiomyomatosisi
KW - lymphatic system
KW - nanoparticles
UR - http://www.scopus.com/inward/record.url?scp=85123405473&partnerID=8YFLogxK
U2 - 10.1080/17425247.2022.2029401
DO - 10.1080/17425247.2022.2029401
M3 - Review article
C2 - 35043744
AN - SCOPUS:85123405473
SN - 1742-5247
VL - 19
SP - 75
EP - 86
JO - Expert Opinion on Drug Delivery
JF - Expert Opinion on Drug Delivery
IS - 1
ER -